microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway

ABSTRACT

Background: A potential role for microRNA-935 (miR-935) has been identified in several cancers but not in non-small cell lung cancer (NSCLC). We hypothesised changes in miR-935 in NSCLC, and proposed mechanisms that may further explain its role in carcinogenesis.

Methods: NSCLC tissue and nearby normal tissue was obtained from 101 patients and was probed by qRT-PCR for miR-935 expression. The role of miR-935 and a potential target (signal transduction factor E2F7) was determined in cell lines by a dual luciferase assay. The function of miR-935 was investigated through metabolic activity (MTT) and transwell migration assays. Western blot and immunocytochemical assays examined protein expression level. Growth of miR-935 transfected or untransfected cells was measured via xenograft tumour formation.

Results: miR-935 was reduced in cancer tissue and was related to lymph node metastases, tumour node metastasis status and poor prognosis (all p < 0.02). In vitro, miR-935 suppressed cell proliferation, migration and invasion in NSCLC cells through targeting E2F7. Furthermore, E2F7 was upregulated in NSCLC tissue associated with poor prognosis (p = 0.0203) of NSCLC patients. miR-935 suppressed the epithelial-mesenchymal transition and AKT pathways in NSCLC and inhibited the tumour growth in vivo.

Conclusion: Altered miR-935 in lung cancer biopsy tissue may be a diagnostic tool and could direct treatment. Involvement in carcinogenesis is implied by its suppression of the development of NSCLC via targeting E2F7 and inhibiting AKT pathway.

KEYWORDS:

• miR-935
• E2F7
• non-small cell lung cancer
• AKT pathway

Summary table

Table

Disclosure statement

No potential conflict of interest was reported by the authors.